Wet AMD- Pipeline Insight, 2019

Wet AMD- Pipeline Insight, 2019

  • Pages: 106
  • Geography: Global
  • Delivery Timeline: 48 Hours
  • Publication: Jul, 2019
  • SKU: DIPI0363
  • Single User License
    (20% Off)
    $1,500.00
  • Site License
    (30% Off)
    $3,000.00
  • Global License
    (40% Off)
    $4,500.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

  1. Overview
  2. Age-Related Macular Degeneration
  3. Risk factors for AMD
  4. Wet AMD - Pathogenesis
  5. Wet AMD – Clinical Features & Diagnosis
  6. Wet AMD – Treatment Options
  7. Pipeline Therapeutics (Active Products)
  8. Comparative Analysis
  9. Late Stage Products (Phase III)
  10. Comparative Analysis
  11. Abicipar: Allergan
  12. Product Description
  13. Research and Development
  14. Product Development Activities
  15. (The list continues)
  16. Mid Stage Products (Phase II)
  17. Comparative Analysis
  18. Early Stage Products (Phase I)
  19. Comparative Analysis
  20. Pre-clinical & Discovery Stage Products
  21. Therapeutic Assessment: Active Products
  22. Assessment by Monotherapy Products
  23. Assessment by Combination Products
  24. Assessment by Route of Administration
  25. Assessment by Stage and Route of Administration
  26. Assessment by Molecule Type
  27. Assessment by Stage and Molecule Type
  28. Inactive Products
  29. Appendix

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

 

Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.